Intra-Cellular Therapies Inc (ITCI) Stock

DelistedNasdaq: ITCIIntra-Cellular Therapies, Inc.

131.92
Final close · Mar 31, 2025

ITCI is no longer traded. Intra-Cellular Therapies was acquired by Johnson & Johnson (JNJ) on April 2, 2025.

Each ITCI share was exchanged for $132.00 in cash. Prices on this page are historical; the last trade was March 31, 2025 at $131.92.

See Johnson & Johnson (JNJ) stock →

Intra-Cellular Therapies stock price history

Split-adjusted closes, 2014–2025

ITCI final trading statistics

Final close
$131.92
Final trading day
Mar 31, 2025
Market cap at delisting
$14.05B
Shares outstanding
106.52M
Final 52-week range
$64.09 – $131.95
Avg. volume (final 3 mo.)
3,179,505
All-time high (split-adj.)
$131.92 · Mar 2025
All-time low (split-adj.)
$7.26 · Oct 2019
Return since IPO
+1219.2%
Beta
0.46
Book value / share
$10.81
Price / book
12.20
Final 52 wk
64.09131.95

Intra-Cellular Therapies earnings per share

Earnings per share

Intra-Cellular Therapies revenue & net income

RevenueNet income

Intra-Cellular Therapies annual financials

Fiscal yearRevenueNet incomeEPS
FY2024$680.85M-$74.7M-$0.73
FY2023$464.37M-$139.7M-$1.46
FY2022$249.13M-$256.3M-$2.72
FY2021$81.71M-$284.1M-$3.50
FY2020$22.53M-$227.0M-$3.24

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.

Intra-Cellular Therapies stock FAQ

What happened to Intra-Cellular Therapies stock?

Intra-Cellular Therapies was acquired by Johnson & Johnson (JNJ) on April 2, 2025. Shareholders received $132.00 in cash for each share. ITCI stock stopped trading on the Nasdaq, with a final close of $131.92 on March 31, 2025.

What did Intra-Cellular Therapies shareholders receive?

Each ITCI share was converted into $132.00 in cash. The deal was valued at about $14.6 billion.

Is ITCI stock still trading?

No. ITCI was delisted from the Nasdaq on April 2, 2025 and no longer trades on a U.S. exchange.

What was the last price of ITCI stock?

ITCI closed at $131.92 on its final trading day, March 31, 2025, for a market value of about $14.05B.

What were Intra-Cellular Therapies's revenue and earnings in its last full fiscal year?

Intra-Cellular Therapies reported revenue of $680.85M and net income of -$74.7M in fiscal 2024, its last full year as a public company.

When did Intra-Cellular Therapies go public?

Intra-Cellular Therapies Inc stock began trading on January 7, 2014.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →